895169-20-7
Chemical Structure
ONO-2952
- CAS No.: 895169-20-7
- Formula:C22H20ClFN2O2
- Molecular Weight:398.86
IUPAC Name: (S)-1-(1'-(4-chloro-2-methoxyphenyl)-5'-fluoro-1',9'-dihydrospiro[cyclopropane-1,4'-pyrido[3,4-b]indol]-2'(3'H)-yl)ethan-1-one
InChIKey: ZBQMTQGDBFZUBG-NRFANRHFSA-N
SMILES: CC(N([C@H]1C2=CC=C(Cl)C=C2OC)CC3(C4=C1NC5=C4C(F)=CC=C5)CC3)=O
Biological Activity: ONO-2952 is a potent, selective and orally active translocator protein 18 kDa (TSPO) antagonist with Ki of 0.33-9.30 nM for rat and human TSPO. ONO-2952 is more selective for TSPO than other receptors, transporters, ion channels and enzymes. ONO-2952 exerts its anti-stress effects through inhibition of excessive activation of noradrenergic system in the brain without the amnesic effect. ONO-2952 has the potential for irritable bowel syndrome treatment[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
ONO-2952 | 99.51% | ONO-2952 is a potent, selective and orally active translocator protein 18 kDa (TSPO) antagonist with Ki of 0.33-9.30 nM for rat and human TSPO. ONO-2952 is more selective for TSPO than other receptors, transporters, ion channels and enzymes. ONO-2952 exerts its anti-stress effects through inhibition of excessive activation of noradrenergic system in the brain without the amnesic effect. ONO-2952 has the potential for irritable bowel syndrome treatment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
ONO-2952 (Standard) | ≥98% | ONO-2952 (Standard) is the analytical standard of ONO-2952 (HY-111191). This product is intended for research and analytical applications. ONO-2952 is a potent, selective and orally active translocator protein 18 Kda (TSPO) antagonist with Ki of 0.33-9.30 nM for rat and human TSPO. ONO-2952 is more selective for TSPO than other receptors, transporters, ion channels and enzymes. ONO-2952 exerts its anti-stress effects through inhibition of excessive activation of noradrenergic system in the brain without the amnesic effect. ONO-2952 has the potential for irritable bowel syndrome treatment. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Mitsui K, et al. Anti-stress effects of ONO-2952, a novel translocator protein 18 kDa antagonist, in rats. Neuropharmacology. 2015 Dec;99:51-66. [Content Brief]
- [2]. Whitehead WE, et al. Randomised clinical trial: exploratory phase 2 study of ONO-2952 in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2017 Jan;45(1):14-26. [Content Brief]
